-
Innovation Ranking
NewInnovation Ranking – Oncternal Therapeutics
Oncternal Therapeutics (Oncternal), formerly GTx Inc, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s has pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid...
-
Innovation Ranking
NewInnovation Ranking – Nektar Therapeutics
Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology among others. Its research and development involve peptides, proteins,...
-
Thematic Analysis
NewPsychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Innovation Ranking
NewInnovation Ranking – VistaGen Therapeutics Inc
VistaGen Therapeutics Inc (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate receptor glycine B intended to treat the major depressive disorder. Its other pipeline products comprise of PH94B treats social anxiety disorder and PH10 nasal spray treats for major depressive disorder. The company offers its products in the form of sprays and oral. It partners with...
-
Innovation Ranking
NewInnovation Ranking – Protagonist Therapeutics Inc
Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US...
-
Innovation Ranking
NewInnovation Ranking – Denali Therapeutics Inc
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. Its proprietary drug delivery platform technologies include an antibody transport vehicle and an enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other...
-
Innovation Ranking
NewInnovation Ranking – Poseida Therapeutics Inc
Poseida Therapeutics Inc (Poseida Therapeutics) is a biopharmaceutical company. It harnesses its proprietary gene engineering platform, to develop next generation cell and gene therapeutics to treat solid tumors and hematological malignancies. The company is investigating its lead product candidate P-BCMA-101, an autologous CAR-T therapy against refractory multiple myeloma. It is also evaluating P-PSMA-101 and P-PSMA-ALL01, allogeneic chimeric antigen receptors for the treatment of prostate cancer; and Dual car (CD19/CD20) targeting solid tumor. Poseida Therapeutics is headquartered in San Diego, California,...
-
Innovation Ranking
NewInnovation Ranking – Intellia Therapeutics Inc
Intellia Therapeutics Inc (Intellia Therapeutics) is a biotechnology company. The company developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. It develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, and primary hyperoxaluria Type 1. Intellia Therapeutics also develops ex vivo programs such as hematopoietic stem cells (HSCs) and chimeric antigen receptor T cells (CAR-T cells). The company’s pipeline products include OTQ923 / HIX763, NTLA-5001. The company conducts genome...
-
Innovation Ranking
NewInnovation Ranking – Rubius Therapeutics Inc
Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company. It focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company's RCT pipeline products comprise of RTX-240, RTX-321 aAPC, RTX-224, RTX-aAPC, and RTX-T1D. Its products under development are intended for the treatment of human papillomavirus 16-positive cancers, non-small cell lung cancer, type 1 diabetes, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. The company also offers...
-
Innovation Ranking
NewInnovation Ranking – Leap Therapeutics Inc
Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. FL-301, a monoclonal antibody that targets Claudin18.2, is being tested in patients with gastric and pancreatic cancer. The company has an agreement with BeiGene Ltd for development rights and...